Macomics announces new hires as it expands its macrophage-based drug discovery and operations
Edinburgh and Cambridge, UK, 18 July 2022 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has made three new appointments to its scientific and operations teams, to support growth and accelerate its R&D.
In the R&D team, Dr Thomas Crozier joins as a Senior Scientist and Dr Yuxin Cui joins as Senior Bioinformatician, with Ms Lisa Seymour joining as Operations Manager and Health & Safety Officer.
The new appointments are based at Macomics’ Cambridge site and bring the total team to 16 across both sites.
Dr Crozier joins from an academic role at the University of Cambridge. He brings over ten years of research experience and extensive knowledge of the use of unbiased genome and proteome-wide approaches to uncover gene and protein function in a range of biological systems. He obtained his PhD from the University of Dundee.
Dr Cui specialises in bioinformatic analysis of large-scale multi-omics data. He is building Macomics’ infrastructure-based bioinformatic engine for target identification and validation to enhance the understanding of the biology of tumour-associated macrophages. He has extensive R&D experience in both academia and industry, at Apitope, including biomarker identification and drug discovery in various solid and liquid cancers and autoimmune diseases. He has been a Research Fellow at Cardiff University and has postdoc experience from the University of Cambridge and the University of Bristol. He obtained his PhD from the University of Nottingham School of Pharmacy.
Prior to joining Macomics, Lisa was at the Wellcome Trust Sanger Institute where she held technical roles of increasing responsibility, including three years as a Licensed Animal Technician and seven years as an Advanced Laboratory Technician in Clinical Microbiology/virology and Parasitology. She also has over eight years of experience as an Administrator. She has a BSC (Hons) in Biomedical Science from Cambridge University and is a member of IOSH and the Royal Society of Biology. She holds a NEBOSH General Certificate in Occupational Health and Safety which includes Management in Health and Safety.
This expansion follows Macomics’ follow-on financing of £4.24 million announced in July 2021. It is developing precision medicines to modulate macrophages for the treatment of cancer. The Company is progressing a diversified portfolio of therapies targeting disease-specific tumour-associated macrophages (‘TAMs’) towards the clinic. Its target discovery platform enables identification and validation of novel macrophage therapeutic targets and is based on its deep understanding of macrophage biology.
Welcoming the new team members and commenting on the Company’s continued growth, Dr Steve Myatt, CEO of Macomics said: “We are progressing well in our vision is to become a leading immuno-oncology company pioneering macrophage-based therapies for the treatment of cancer. We are delighted that this vision and strategy have enabled us to attract world-class talent to our team, as we advance our early-stage antibody R&D programs. Our new colleagues bring additional expertise and relevant experience that I know will make a positive contribution.”